JP Morgan Chase’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $141K | Sell |
50,169
-6,368
| -11% | -$27.6K | ﹤0.01% | 5653 |
|
|
2025
Q4 | $201K | Buy |
56,537
+11,472
| +25% | +$70.3K | ﹤0.01% | 5539 |
|
|
2025
Q3 | $401K | Sell |
45,065
-4,073
| -8% | -$41.3K | ﹤0.01% | 5157 |
|
|
2025
Q2 | $453K | Buy |
49,138
+566
| +1% | +$4.83K | ﹤0.01% | 4839 |
|
|
2025
Q1 | $417K | Buy |
48,572
+7,749
| +19% | +$73.2K | ﹤0.01% | 4880 |
|
|
2024
Q4 | $438K | Sell |
40,823
-1,742
| -4% | -$13.4K | ﹤0.01% | 5115 |
|
|
2024
Q3 | $242K | Buy |
42,565
+1,191
| +3% | +$6.87K | ﹤0.01% | 5319 |
|
|
2024
Q2 | $175K | Sell |
41,374
-6,535
| -14% | -$26.4K | ﹤0.01% | 5231 |
|
|
2024
Q1 | $244K | Sell |
47,909
-16,527
| -26% | -$93K | ﹤0.01% | 5240 |
|
|
2023
Q4 | $600K | Buy |
64,436
+352
| +0.5% | +$2.42K | ﹤0.01% | 4673 |
|
|
2023
Q3 | $420K | Buy |
64,084
+4,798
| +8% | +$38.2K | ﹤0.01% | 4580 |
|
|
2023
Q2 | $482K | Buy |
59,286
+1,564
| +3% | +$13.4K | ﹤0.01% | 4516 |
|
|
2023
Q1 | $495K | Buy |
57,722
+13,748
| +31% | +$137K | ﹤0.01% | 4511 |
|
|
2022
Q4 | $407K | Buy |
43,974
+253
| +0.6% | +$2.7K | ﹤0.01% | 4647 |
|
|
2022
Q3 | $452K | Buy |
43,721
+3,026
| +7% | +$31.9K | ﹤0.01% | 4527 |
|
|
2022
Q2 | $408K | Sell |
40,695
-785
| -2% | -$7.44K | ﹤0.01% | 4688 |
|
|
2022
Q1 | $511K | Buy |
41,480
+8,141
| +24% | +$100K | ﹤0.01% | 4680 |
|
|
2021
Q4 | $578K | Buy |
33,339
+8,741
| +36% | +$166K | ﹤0.01% | 4731 |
|
|
2021
Q3 | $440K | Sell |
24,598
-8,765
| -26% | -$174K | ﹤0.01% | 4802 |
|
|
2021
Q2 | $763K | Buy |
33,363
+11,033
| +49% | +$163K | ﹤0.01% | 4458 |
|
|
2021
Q1 | $334K | Sell |
22,330
-40,424
| -64% | -$441K | ﹤0.01% | 4905 |
|
|
2020
Q4 | $339K | Buy |
62,754
+43,055
| +219% | +$227K | ﹤0.01% | 4583 |
|
|
2020
Q3 | $93K | Sell |
19,699
-22,185
| -53% | -$95.5K | ﹤0.01% | 4723 |
|
|
2020
Q2 | $206K | Buy |
41,884
+28,139
| +205% | +$106K | ﹤0.01% | 4244 |
|
|
2020
Q1 | $43K | Sell |
13,745
-329
| -2% | -$1.15K | ﹤0.01% | 4770 |
|
|
2019
Q4 | $36K | Hold |
14,074
| – | – | ﹤0.01% | 5211 |
|
|
2019
Q3 | $44K | Buy |
14,074
+2,283
| +19% | +$6.59K | ﹤0.01% | 5224 |
|
|
2019
Q2 | $38K | Buy |
+11,791
| New | +$36.6K | ﹤0.01% | 5277 |
|
|
2018
Q2 | – | Sell |
-7,939
| Closed | -$22K | – | 5540 |
|
|
2018
Q1 | $22K | Sell |
7,939
-111
| -1% | -$314 | ﹤0.01% | 5057 |
|
|
2017
Q4 | $26K | Buy |
+8,050
| New | +$31.7K | ﹤0.01% | 5098 |
|
|
2017
Q2 | – | Sell |
-18,261
| Closed | -$105K | – | 4948 |
|
|
2017
Q1 | $105K | Buy |
+18,261
| New | +$94.3K | ﹤0.01% | 4311 |
|
Other funds holding AVXL
VCM
SF
VPM
JP Morgan Chase's AVXL Position: Q1 2026 in Review
JP Morgan Chase reduced its Anavex Life Sciences (AVXL) stake by 11% in Q1 2026, selling an estimated $27.6K and leaving 50,169 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #5653.
JP Morgan Chase first reported a position in AVXL in Q1 2017 and has held it in 31 quarters since. The position peaked at $763K in Q2 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.
- JP Morgan Chase held 50,169 shares of Anavex Life Sciences worth $141K as of Q1 2026.
- JP Morgan Chase sold 6,368 Anavex Life Sciences shares in Q1 2026, an estimated $27.6K.
- Anavex Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5653 holding.
- JP Morgan Chase first reported a position in Anavex Life Sciences in Q1 2017 and has held it in 31 quarters since.
- JP Morgan Chase's Anavex Life Sciences position peaked at $763K in Q2 2021.
- 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.